Asim Pervaiz1,2, Michael Zepp2, Saqib Mahmood1, Doaa Mohamed Ali2, Martin R Berger3, Hassan Adwan2,4. 1. Institute of Biomedical and Allied Health Sciences, University of Health Sciences, Lahore, Pakistan. 2. Toxicology and Chemotherapy Unit, German Cancer Research Centre (DKFZ), Im Neuenheimer Feld 581, 69120, Heidelberg, Germany. 3. Toxicology and Chemotherapy Unit, German Cancer Research Centre (DKFZ), Im Neuenheimer Feld 581, 69120, Heidelberg, Germany. m.berger@dkfz.de. 4. German University of Cairo, Cairo, Egypt.
Abstract
PURPOSE: Bone metastasis is observed in up to 70% of breast cancer patients. The currently available treatment options are palliative in nature. Chemokine receptor 5 (CCR5) has gained attention as therapeutic target in various malignancies. Here, we investigated the effects of targeting CCR5 by its antagonist maraviroc in metastatic breast cancer cells. METHODS: In response to maraviroc exposure, cytotoxicity was assessed using an MTT proliferation assay, whereas the effects on colony formation and migration were assessed using colony formation, transwell chamber migration and scratch wound healing assays, respectively. Apoptosis-related activities were investigated using nuclear staining, annexin-V FITC staining and Western blotting. Cell cycle changes were analysed using flow cytometry and qRT-PCR for cell cycle relevant genes. A nude rat model for breast cancer bone metastasis was used to evaluate the in vivo efficacy of CCR5 targeting by maraviroc. Circulatory levels of the three cognate ligands for CCR5 (CCL3, CCL4, CCL5) were analysed in sera of breast cancer patients using ELISA. RESULTS: We found that blockade of CCR5 attenuated the proliferation, colony formation and migration of metastatic breast cancer cells, and induced apoptosis and arrest in the G1 phase of the cell cycle. Expression profiling highlighted the involvement of cell cycle related signalling cascades. We also found that treatment with maraviroc significantly inhibited bone metastasis in nude rats implanted with MDA-MB-231 breast cancer cells. Finally, we found that the circulatory levels of three cognate ligands for the CCR5 receptor varied between breast cancer patients and healthy controls. CONCLUSION: Our findings indicate that targeting CCR5 may be an effective strategy to combat breast cancer bone metastasis.
PURPOSE: Bone metastasis is observed in up to 70% of breast cancer patients. The currently available treatment options are palliative in nature. Chemokine receptor 5 (CCR5) has gained attention as therapeutic target in various malignancies. Here, we investigated the effects of targeting CCR5 by its antagonist maraviroc in metastatic breast cancer cells. METHODS: In response to maraviroc exposure, cytotoxicity was assessed using an MTT proliferation assay, whereas the effects on colony formation and migration were assessed using colony formation, transwell chamber migration and scratch wound healing assays, respectively. Apoptosis-related activities were investigated using nuclear staining, annexin-V FITC staining and Western blotting. Cell cycle changes were analysed using flow cytometry and qRT-PCR for cell cycle relevant genes. A nude rat model for breast cancer bone metastasis was used to evaluate the in vivo efficacy of CCR5 targeting by maraviroc. Circulatory levels of the three cognate ligands for CCR5 (CCL3, CCL4, CCL5) were analysed in sera of breast cancer patients using ELISA. RESULTS: We found that blockade of CCR5 attenuated the proliferation, colony formation and migration of metastatic breast cancer cells, and induced apoptosis and arrest in the G1 phase of the cell cycle. Expression profiling highlighted the involvement of cell cycle related signalling cascades. We also found that treatment with maraviroc significantly inhibited bone metastasis in nude rats implanted with MDA-MB-231 breast cancer cells. Finally, we found that the circulatory levels of three cognate ligands for the CCR5 receptor varied between breast cancer patients and healthy controls. CONCLUSION: Our findings indicate that targeting CCR5 may be an effective strategy to combat breast cancer bone metastasis.
Entities:
Keywords:
Apoptosis; Bone metastasis; Breast cancer; CCR5; Cell cycle arrest; Maraviroc
Authors: L Gerratana; V Fanotto; M Bonotto; S Bolzonello; A M Minisini; G Fasola; F Puglisi Journal: Clin Exp Metastasis Date: 2015-01-29 Impact factor: 5.150
Authors: Lindsey A Torre; Freddie Bray; Rebecca L Siegel; Jacques Ferlay; Joannie Lortet-Tieulent; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2015-02-04 Impact factor: 508.702
Authors: Maria E Reyes; Marjorie de La Fuente; Marcela Hermoso; Carmen G Ili; Priscilla Brebi Journal: Front Immunol Date: 2020-05-15 Impact factor: 7.561
Authors: Joel Henrique Ellwanger; Bruna Kulmann-Leal; Valéria de Lima Kaminski; Andressa Gonçalves Rodrigues; Marcelo Alves de Souza Bragatte; José Artur Bogo Chies Journal: Virus Res Date: 2020-05-30 Impact factor: 3.303
Authors: Michaela Kripnerová; Hamendra Singh Parmar; Jiří Šána; Alena Kopková; Lenka Radová; Sieghart Sopper; Krzysztof Biernacki; Jan Jedlička; Michaela Kohoutová; Jitka Kuncová; Jan Peychl; Emil Rudolf; Miroslav Červinka; Zbyněk Houdek; Pavel Dvořák; Kateřina Houfková; Martin Pešta; Zdeněk Tůma; Martina Dolejšová; Filip Tichánek; Václav Babuška; Martin Leba; Ondřej Slabý; Jiří Hatina Journal: J Clin Med Date: 2021-05-25 Impact factor: 4.241
Authors: Heidi G Parker; Deepika Dhawan; Alex C Harris; Jose A Ramos-Vara; Brian W Davis; Deborah W Knapp; Elaine A Ostrander Journal: BMC Cancer Date: 2020-03-24 Impact factor: 4.430